argenx develops antibody medicines for autoimmune and neuromuscular diseases, with its main product VYVGART. Analyst consensus is Strong Buy, based on the latest ratings from 13 firms (12 buy, 1 hold, 0 sell). Over the past 90 days StreetAlpha recorded 6 whale options trades in ARGX, 33% of them bullish and 67% bearish. In the past 30 days there were 9 dark pool prints.
Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Citigroup | Target raised | Buy | |
| Oct 23 | Morgan Stanley | Target lowered | Buy | |
| Oct 23 | Wells Fargo | Target lowered | Buy | |
| Oct 23 | Evercore ISI Group | Target raised | Buy | |
| Oct 23 | Baird | Target raised | Hold |
Whale Options Flow
90DNo whale options trades in ARGX in the last 90 days.
Dark Pool
30DAI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ARGX is in one of them and how their past ARGX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered ARGX in an article yet. Here's the latest on the wider market.
ARGX Congress Trades
All congress trades →
| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Alan ArmstrongHouse | Buy | $1K – $15K | Mar 30, 2026 | Jul 21, 2026 | 113 d |
| Sean DuffyExecutive branch | Sell | $1K – $15K | Feb 11, 2025 | May 14, 2025 | 92 d |
| Dan GoldmanD · NY | Sell | $1K – $15K | Jul 10, 2023 | Aug 13, 2023 | 34 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Argenx SE
argenx is a biopharmaceutical company that develops antibody medicines for autoimmune and neuromuscular diseases. Its main product, VYVGART, is approved for several conditions, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP). The company sells its medicines to patients and works with healthcare professionals, and it is developing a range of other candidates in clinical trials. It is based in Zwijnaarde.
- Headquarters
- Zwijnaarde